Personalized oncology represents a paradigm shift in cancer care, demanding high-fidelity preclinical models and tailored therapeutic strategies. This special issue, titled "Advanced Bioprinting Materials for Personalized Cancer Therapeutics and Drug Screening," aims to highlight the pivotal role of innovative biomaterials in advancing 3D bioprinting technologies for transformative cancer research and precision medicine.

We seek to curate cutting-edge research and reviews that focus on the design, synthesis, and functionalization of next-generation bioinks and bioprinting materials. These materials are engineered to recapitulate the complex, patient-specific tumor microenvironment (TME), encompassing heterogeneous cell populations, extracellular matrix (ECM) cues, and dynamic biochemical gradients. Contributions are encouraged on topics such as smart, responsive, or bioactive materials that enable the fabrication of physiologically relevant in vitro tumor models for high-throughput drug screening, the prediction of therapeutic resistance, and the evaluation of combination therapies.

A core objective is to showcase how material innovations directly empower personalized therapeutic platforms. This includes bioprinted constructs for testing patient-derived organoids or cells, materials facilitating localized and controlled drug delivery, and systems for developing customized implants or in vitro platforms that guide clinical decision-making. By bridging materials science, biofabrication, and translational oncology, this special issue will provide a comprehensive forum to discuss the challenges and breakthroughs in creating clinically relevant, bioprinted solutinos that move beyond one-size-fits-all approaches to cancer treatment.

We invite original research articles, reviews, and perspectives that explore the intersection of advanced biomaterials and bioprinting to accelerate the development of personalized cancer therapeutics and predictive drug screening platforms.

Keywords: 3D Bioprinting, Biomaterials, Personalized Cancer Therapy, Tumor Microenvironment, Drug Screening, Bioinks, Patient-Derived Models